(Q49023772)

17 February 2018

title

Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. (English)

1 reference

17 February 2018

0 references

0 references

1 reference

1

1 reference

17 February 2018

Bradley Hyman

4

object named as

Bradley T Hyman

1 reference

17 February 2018

3

Stephanie Soscia

1 reference

17 February 2018

Rudolph E. Tanzi

6

object named as

Rudolph E Tanzi

1 reference

17 February 2018

Katya A Tseitlin

2

object named as

Katya A Tseitlin

1 reference

17 February 2018

author name string

Michael C Irizarry

5

1 reference

17 February 2018

language of work or name

English

0 references

publication date

21 February 2005

1 reference

17 February 2018

Journal of Biological Chemistry

published in

1 reference

17 February 2018

volume

280

1 reference

17 February 2018

issue

17

1 reference

17 February 2018

page(s)

17458-17463

1 reference

17 February 2018

Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

The galvanization of beta-amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

[Systemic changes of the immune system in patients with Alzheimer's dementia]

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Dityrosine Cross-Linked Aβ Peptides: Fibrillar β-Structure in Aβ(1-40) Is Conducive to Formation of Dityrosine Cross-Links but a Dityrosine Cross-Link in Aβ(8-14) Does Not Induce β-Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Rapid induction of Alzheimer A beta amyloid formation by zinc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Self-reactive antibodies (natural autoantibodies) in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

Autoanticorps, tolérance et auto-immunité

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M414176200

21 January 2018

Identifiers

DOI

10.1074/JBC.M414176200

1 reference

17 February 2018

1 reference

17 February 2018